Healthcare Industry News: blood glucose monitoring
News Release - February 15, 2007
Insulet Corporation Promotes Luis Malave to Chief Operating OfficerBEDFORD, Mass., Feb. 15 (HSMN NewsFeed) -- Insulet Corporation announced today that Luis Malave has been promoted to the position of Chief Operating Officer. Since 2002, Mr. Malave has served as the company's Senior Vice President of Research, Development & Engineering. In his new role, Mr. Malave will be responsible for the day-to-day operations of the company, including manufacturing, research and development, and quality and regulatory affairs. Insulet Corporation is the developer and manufacturer of the OmniPodŽ Insulin Management System, an innovative product for the treatment of diabetes that brings together safe, reliable, continuous subcutaneous insulin infusion and blood glucose monitoring in a discreet and easy-to-use, two-part system.
With more than 20 years of experience in the medical device industry, Mr. Malave spent six years in senior-level positions with Medtronic MiniMed in Northridge, California prior to joining Insulet. During his tenure there, he was responsible for a broad range of market-impacting projects including the development of several insulin pump systems.
"Luis has proven to be a tremendous asset in the development of our OmniPod System and an integral part of our management team," said Duane DeSisto, Insulet President and CEO. "The expertise that he brings to the position of COO will be invaluable to helping us expand our market reach and achieve our business goals."
Mr. Malave earned Bachelors degrees in Mathematics and Computer Science from the University of Minnesota, a Masters degree in Software Engineering from the University of St. Thomas, and an MBA from the University of Maryland. He and his family live in Reading, Massachusetts.
About Insulet Corporation
Founded in 2000, Insulet Corporation is a privately-held medical device company located in Bedford, Massachusetts. The company seeks to improve the lives of people with diabetes and expand the use of continuous subcutaneous insulin infusion (CSII) therapy through innovative technology and feedback from people with diabetes and healthcare professionals. Insulet Corporation develops, manufactures and markets the OmniPod Insulin Management System, an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes.
For more information about Insulet Corporation and the OmniPod System, please visit our website at www.insulet.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.